Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Adamax vs Zilucoplan (Zilbrysq)
An educational, source-based comparison of Adamax and Zilucoplan (Zilbrysq) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of Semax with additional N-terminal adamantyl group. Research suggests enhanced stability and penetration across the blood-brain barrier, with amplified neurotrophic and neuroprotective effects compared to parent compound.
- Neuroprotection in acute ischemia
- Cognitive enhancement in healthy adults
- Recovery from traumatic brain injury
- • Russian-origin research; limited Western clinical data.
- • Not FDA-approved.
Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- • FDA-approved 2023.
- • Requires meningococcal vaccination — risk of serious meningococcal infection.
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Adamax | Adamax pharmacokinetics and neuroprotection | Molecular Neurobiology | 2019 | Enhanced BBB penetration and neuroprotective efficacy versus Semax in rodent models. |
| Zilucoplan (Zilbrysq) | RAISE phase 3 trial of zilucoplan in gMG | Lancet Neurology | 2023 | Significant improvement in MG-ADL and QMG scores vs placebo at week 12. |
Side-effect & safety grid
- Russian-origin research; limited Western clinical data.
- Not FDA-approved.
- FDA-approved 2023.
- Requires meningococcal vaccination — risk of serious meningococcal infection.
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Adamax vs Zilucoplan (Zilbrysq) — Key differences
- Class: Adamax is classified as Nootropic · Neuroprotection, while Zilucoplan (Zilbrysq) is Complement Inhibitor · Neuromuscular.
- Primary research focus: Adamax — neuroprotection in acute ischemia; Zilucoplan (Zilbrysq) — generalized myasthenia gravis (anti-achr antibody positive).
- Tag: Cognition vs FDA-Approved · Neuromuscular.